Registry of Lobbyists
Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
| Subject matters | Details | Categories |
|---|---|---|
|
Health
|
Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
|
Policies or Program
|
|
Health
|
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
|
Policies or Program
|
|
Health
|
Discussion on the opioids crisis and the Health minister's expectations from pharmaceutical manufacturers
|
Policies or Program
|
|
Economic Development, Research and Development, Science and Technology, Taxation and Finance
|
Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
|
Policies or Program
|
|
Health
|
Policies aimed at facilitating generic drugs repurposing.
|
Policies or Program
|
|
Economic Development, Health, Industry
|
Policies aimed at reinforcing pharmaceutical supply chain.
|
Policies or Program
|
|
Economic Development, Health, Industry
|
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
|
Grant, Contribution or Other Financial Benefit
|
Address:
6111 Royalmount avenue, suite 100
Montreal, QC H4P 2T4
Canada
Telephone number:
514-340-9800
Web address:
https://www.pharmascience.com
Martin Arès, Chief Executive Officer
Pharmascience Inc. / Pharmascience Inc. is not a coalition.
The activities of Pharmascience Inc. / Pharmascience Inc. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Pharmascience Inc. / Pharmascience Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Delaney Cullinan | No public offices held
Firm: Earnscliffe Strategy Group